免疫原性
中和
病毒学
佐剂
生物
中和抗体
疫苗效力
化学
接种疫苗
免疫系统
免疫学
病毒
作者
Rui Wang,Hongpeng Huang,Chulin Yu,Chunyun Sun,Juan Ma,Desheng Kong,Yin-Shiou Lin,Dong Zhao,Shaozheng Zhou,Jianbo Lu,Sai Cao,Yanjun Zhang,Chunxia Luo,Xuefeng Li,Yang Wang,Liangzhi Xie
标识
DOI:10.1007/s11427-022-2207-7
摘要
Multivalent vaccines combining crucial mutations from phylogenetically divergent variants could be an effective approach to defend against existing and future SARS-CoV-2 variants. In this study, we developed a tetravalent COVID-19 vaccine SCTV01E, based on the trimeric Spike protein of SARS-CoV-2 variants Alpha, Beta, Delta, and Omicron BA.1, with a squalene-based oil-in-water adjuvant SCT-VA02B. In the immunogenicity studies in naïve BALB/c and C57BL/6J mice, SCTV01E exhibited the most favorable immunogenic characteristics to induce balanced and broad-spectrum neutralizing potencies against pre-Omicron variants (D614G, Alpha, Beta, and Delta) and newly emerging Omicron subvariants (BA.1, BA.1.1, BA.2, BA.3, and BA.4/5). Booster studies in C57BL/6J mice previously immunized with D614G monovalent vaccine demonstrated superior neutralizing capacities of SCTV01E against Omicron subvariants, compared with the D614G booster regimen. Furthermore, SCTV01E vaccination elicited naïve and central memory T cell responses to SARS-CoV-2 ancestral strain and Omicron spike peptides. Together, our comprehensive immunogenicity evaluation results indicate that SCTV01E could become an important COVID-19 vaccine platform to combat surging infections caused by the highly immune evasive BA.4/5 variants. SCTV01E is currently being studied in a head-to-head immunogenicity comparison phase 3 clinical study with inactivated and mRNA vaccines (NCT05323461).
科研通智能强力驱动
Strongly Powered by AbleSci AI